In this study, we document that Toxoplasma gondii differentiation and reactivation are mediated by systemic CD8 T-cell dysfunction during chronic infection. We demonstrate that CD8 + T-cell exhaustion occurs despite control of parasitemia during early-chronic toxoplasmosis. During later phases, these cells become exhausted, leading to parasite reactivation and mortality. Concomitant with increased CD8 + T-cell apoptosis and decreased effector response, this dysfunction is characterized by a graded elevation in expression of inhibitory receptor PD-1 on these cells in both lymphoid and nonlymphoid tissue. Blockade of the PD-1-PDL-1 pathway reinvigorates this suboptimal CD8 + T-cell response, resulting in control of parasite reactivation and prevention of mortality in chronically infected animals. To the best of our knowledge, this report is unique in showing that exposure to a persistent pathogen despite initial control of parasitemia can lead to CD8 + T-cell dysfunction and parasite reactivation.
recrudescence | Toxoplasma gondii | adaptive immunity T oxoplasmic encephalitis (TE) from reactivation of chronic Toxoplasma infection affects 24% to 47% of HIV-infected Toxoplasma-seropositive patients in the United States (1-3). Although the incidence of TE among AIDS patients declined threefold in the United States because of prophylactic treatment and highly active antiretroviral therapy, it still remains a significant problem in developing countries (4, 5) . Hence, understanding the mechanisms responsible for parasite reactivation in chronically infected hosts is critical for evolving strategies for the development of immunotherapeutic agents against the parasite.
In the intermediate host, Toxoplasma undergoes stage conversion between the rapidly replicating tachyzoite that is thought to be responsible for acute toxoplasmosis and the slowly replicating, relatively quiescent, primarily encysted bradyzoite stage that can persist possibly for life (6) . Effective CD8 + T-cell response, critical for control of both acute and chronic Toxoplasmosis in susceptible mice strains paradoxically do not ensure their long-term survival (7) . Poor long-term survival of Toxoplasmainfected B10 mice is associated with reduced number of intracerebral T cells and TE development (8) . Additionally, depletion of CD8 + T cells rather than CD4 + T cells had a greater effect on mortality of chronically infected animals (9) . Taken together, these studies suggest that although critical for preventing parasite reactivation, CD8 + T-cell responses during late-chronic infection are incapable of preventing mortality in infected mice. However, the mechanism underlying this apparently ineffective CD8 + T-cell response during late-chronic infection has not been studied and it remains to be determined if this defect is responsible for loss of parasite control. We therefore tested whether CD8 + T cells during late-chronic toxoplasmosis become dysfunctional, as reported in some viral infections (10) .
This article is unique in demonstrating that CD8 + T cells during later phases of chronic toxoplasmosis are unable to mount a potent anamnestic response, a hallmark of robust adaptive immunity. Moreover, CD8 + T cells from these mice exhibit a progressive increase in expression of inhibitory molecule PD-1 with concomitant parasite reactivation. In vivo blockade of PD-1 interaction with its receptor PDL-1 not only augmented polyfunctional CD8 + T-cell response, but it also inhibited parasite recrudescence and prevented the mortality of chronically infected mice in a CD8 + T-cell-dependent manner. To the best of our knowledge, this report of parasite reactivation caused by PD-1 mediated CD8 + T-cell dysfunction is unique. (Fig. 1A) . Host innate and adaptive immunity are thought to cause differentiation of tachyzoites into chronic slow growing bradyzoites (12) . Because encysted parasites can persist for life and are not believed to be associated with disease pathology, several studies have postulated that rather than an incidence of parasites, which remain primarily encysted in chronically infected brains, the degree of bradyzoite-tachyzoite interconversion is a better hallmark of disease reactivation (6, 13, 14) . Therefore, we assayed parasite reactivation by changes in parasite stage-specific gene expression. We measured the transcription of the tachyzoite stage-specific Enolase-II (ENO-2) and the bradyzoite stage-specific Enolase-I (ENO-1), two genes that have been previously shown to change in very high levels (15) (16) (17) . Concomitant with poor survival of Toxoplasma gondii-infected mice during the latechronic phase, increased ENO-2 expression and decreased ENO-1 expression was noted at week 7 postinfection, suggesting parasite reactivation (Fig. 1B) . Interestingly, we observed that expression of both ENO-2 and ENO-1 occurs at week 10, indicating that despite limited tachyzoite to bradyzoite differentiation, the parasites are still undergoing reactivation (i.e., a bradyzoite to tachyzoite conversion) (Fig. 1B) . To verify that ENO-2 and ENO-1 corresponded to the tachyzoite and bradyzoite stage of T. gondii, the gene expression of the parasite were examined again in vivo using established models of acute and chronic infection. Mice were infected with Type I RH strain (lethal acute infection) or Type II ME49 strain (chronic) (18, 19) . Some of the ME49-infected animals were treated with drugs known to control reactivation of chronic infection (18, 19) . As expected, RH-infected mice exhibited high tachyzoite-specific gene expression (SAG-1, ENO-2) and minimal bradyzoite-spe-cific gene expression (BAG-1, ENO-1) (Fig. S1 ). In contrast, drug-treated mice showed reduced SAG-1 and ENO-2 transcript levels and increased BAG-1 and ENO-1 expression vis-à-vis untreated ME49 infected mice. Next, we further confirmed the stage-specificity of the above markers using Type II parasites maintained in vitro under tachyzoite-or bradyzoite-inducing conditions (20) . Immunofluorescent microscopic analysis showed that stage-specific protein expression corresponded with our stage-specific transcript profile (Fig. S1 ). Tissue cysts in brain occur almost exclusively in neurons and not in leukocytes during the chronic phase (21) . Because a recent study has shown that leukocytes can be used for parasite dissemination during the acute phase (22), we examined these cells for parasitization as a further readout of reactivation. To characterize, whether parasite reactivation increased the frequency of Toxoplasma-infected leukocytes, mononuclear leukocyte-gated blood and brain cells were examined for parasites by flow cytometry. Although minimal infection of blood and brain leukocytes was noted during the early-chronic phase, high infection rates were observed during the late-chronic period, particularly in moribund mice (Fig. 1C) . Similar to observations noted by Courret et al. (22) , the level of parasite infection was much higher in circulating leukocytes vis-à-vis brain leukocytes assayed at the same time. It has been speculated that this may be because of multiple populations of nonleukocytic brain lineages that are differentially permissive to T. gondii in the brain (22) . Next, we assessed if reactivated parasites preferentially infected specific leukocyte subsets in a site-dependent manner. Irrespective of tissue, the majority of parasitized leukocytes corresponded to a myeloid phenotype (CD3CD19NK1.1 − CD11b hi F4/80 + GR1 + ) (Fig. S2 ). Taken together, our data suggest that during the late-chronic phase, parasite-stage conversion results in reactivation of disease.
Results

Toxoplasma-Infected
As Toxoplasma infection induces a robust CD8 + T-cell immunity that is known to be critical for long-term protection, it is enigmatic that this potent immune response failed to prevent recrudescence of infection (9) . By measuring the kinetics of CD8 + T-cell immunity we demonstrate that CD8 + T-cell response peaked at weeks 3 to 5 postinfection followed by gradual contraction (Fig. 1D ). Concomitant with this process, reduced frequency of splenic and brain IFN-γ + Granzyme B + and IFN-γ − Granzyme B + CD8 + T cells was noted (Fig. 1E) . One of the quintessential features of robust long-term CD8 + T-cell immunity is the generation of a rapid response upon secondary challenge (23) . To verify the potency of secondary response, Toxoplasma-infected animals were rechallenged during the early-chronic and late-chronic phases and assessed for cycling CD8 + T cells (Fig. 1F ). Mice rechallenged during the earlychronic phase demonstrated a significant increase in absolute number of proliferating splenic CD8 + T cells over unchallenged mice (Fig. 1F ). In contrast, no significant change in cycling CD8 + T cells was noted in rechallenged animals during the late-chronic phase. These data clearly demonstrate that a potent recall response, a hallmark of robust CD8 + T-cell immunity, is compromised during later stages of chronic toxoplasmosis.
CD8
+ T Cells Up-Regulate PD-1 During Chronic Toxoplasmosis. The role of PD-1 in mediating dysfunction in chronic parasitic models has not been extensively addressed (24, 25) . Although PD-1 expression during toxoplasmosis has been recently reported (26) , its role in mediating CD8 + T-cell dysfunction or pathogenesis as shown in chronic viral models like lymphocytic choriomeningitis virus (LCMV), hepatitis B virus (HBV), hepatitis C virus (HCV), and HIV (27) , is currently unknown. Analysis of CD8 + T cells revealed a progressive increase of PD-1 expression and frequency during the chronic stage of parasite infection (Fig. 2) . Of the two PD-1 ligands, PDL-1 and PDL-2, the mean fluorescence intensity (MFI) of the former but not the latter increased during the course of chronic infection (Fig. S3) .
Because increased PD-1 MFI correlated with decreased frequency of splenic IFN-γ + CD8 + T cells, we hypothesized that PD-1 hi CD8
+ T cells would have reduced capacity to release IFN-γ. To address this theory, we measured the proportion of IFN-γ-producing cells within PD-1 hi CD8 + and PD-1 int CD8 + Tcell population. No significant difference in cytokine-positive cells between the two populations was noted (Fig. S4) . Although this finding suggests that PD-1 expression does not directly regulate IFN-γ production in CD8 + T cells, the role of other factors, such as the extent and duration of PD-1 cross-linking and frequency of PD-1-PDL-1 engagement in regulating CD8 + Tcell-mediated IFN-γ production, cannot be ruled out. Irrespective of the time point, very few PD-1 lo cells produced IFN-γ, indicating that an overwhelming majority of CD8 + T cells in this subset are naive. Although we did not observe a significant difference in frequency of IFN-γ + CD8 + T cells between the PD-1 hi and PD-1 int CD8 + T-cell subsets, we hypothesized that the reduced frequency of splenic IFN-γ + CD8 + T cells during latechronic infection could be because of apoptosis of PD-1 hi cells. As recent studies have suggested that apoptosis can be coupled to cell-cycle progression (28, 29) , we incubated splenocytes from week 7-infected mice for 5 h at 37°C and stained for CD8, PD-1, Ki-67, and active caspase-3, the active form of the apoptosis-related cysteine peptidase. Although cycling PD-1 hi CD8 + T cells exhibited a higher expression of active caspase-3 than noncycling PD-1 hi CD8 + T cells, PD-1 int/lo cells had a much lower MFI than cycling or noncycling PD-1 hi cells (Fig. S4) , suggesting that cycling PD-1 hi CD8 + T cells exhibit poor survival. Because PD-1 has been reported to be transiently expressed in acute viral infections (27) , increased PD-1 MFI during later stages of chronic Toxoplasmosis could be because of a generation of new PD-1-expressing effectors in response to parasite recrudescence. To address this theory, we used a BrdU pulsechase approach and then measured PD-1 expression on BrdU + and Brdu − CD8 + T cells during the early-chronic and late-chronic phases (Fig. S5) . Dramatic increase in PD-1 MFI and frequency of PD-1 hi cells was noted only in BrdU-labeled fraction. This finding suggests that PD-1 up-regulation is a graded process and the majority of PD-1 hi CD8
+ T cells at week 7 postinfection are not new effector cells generated in response to parasite recrudescence.
Considering that a majority of PD-1 hi CD8 + T cells during the late-chronic phase are not newly generated effectors, we wanted to address if the control of infection during the early or later phases of infection would result in reduced CD8 exhaustion. To evaluate this, we treated mice with sulfamethoxazole and trimethoprim at various time points postinfection, as show in Fig. S6 (19) . Because reduced antigen burden in drug-treated mice can result in increased naive T-cell numbers, which can potentially confound interpretation of data, we analyzed brain, a tissue known to recruit CD8 + T cells in a strictly antigen-specific manner (30) . Only early initiation of drug treatment resulted in decreased PD-1 MFI on CD8 + T cells during the late-chronic phase (Fig. S6) . Moreover, CD8 + T cells from these mice exhibited a higher proportion of IFN-γ + GranzymeB − and IFN-γ + GranzymeB + CD8 + T cells (Fig.  S6) . However, IFN-γ − GranzymeB + CD8 + T cells underwent a moderate decrease in these animals (Fig. S6) . This finding may be attributed to attenuated inflammation or antigen load in drugtreated mice, which can result in suboptimal development or maintenance of Granzyme B-expressing short-lived effector subset (31, 32) . Combined, these data suggest that control of infection during the early phases of infection may be critical for minimizing induction of CD8 dysfunction during the chronic phase.
Blockade of PD-1-PDL-1 Pathway Reinvigorates CD8 + T-Cell Response.
Next, we addressed if a dysfunctional CD8 + T-cell response could be revived by blocking the PD-1-PDL-1 pathway. To address this, animals were administered a nondepleting anti-PDL-1 antibody starting at week 5 postinfection for a period of 2 wk and, thereafter, the CD8 + T-cell response in the spleen, liver, and brain were quantified (33) . Although significant increase in absolute number of CD8 + T cells was noted in all of the tissues examined, the most dramatic increase occurred in brain (Fig.  3A) . To determine if this increase was because of enhanced proliferation, we measured Ki-67 expression in the CD8 + T cells. Unlike the spleen and liver, we were unable to detect increased frequency of cycling CD8 + T cells in anti-PDL-1 treated groups in the brain (Fig. 3B) . Taken together, these data suggest that one of the mechanisms for increased brain CD8 + T cells in anti-PDL-1 treated mice is not in situ proliferation but possibly increased recruitment of these cells to the tissue.
As IFN-γ production (34) and cytotoxicity (35) are known to be critical for control of toxoplasmosis, we examined if blockade with anti-PDL-1 augmented these functions within the CD8 + Tcell population. Anti-PDL-1 treatment increased the frequency of IFN-γ + Granzyme B + and IFN-γ − Granzyme B + CD8 + T cells in the spleen and brain, as well as ex vivo cytotoxicity of splenic CD8 + T cells (Fig. 3 C and D) . We then measured, if anti-PDL-1 treatment decreased the frequency of PD-1 hi cells. Surprisingly, PD-1-PDL-1 blockade caused a further increase in the frequency of PD-1-expressing CD8 + T cells (Fig. 3E ). Because we demonstrated that high PD-1 expression was associated with apoptosis, we determined if rescue of CD8 + T-cell response by PD-1-PDL-1 blockade was because of reduced apoptosis. To address this under steady-state conditions without confounding effects of proliferation and graded PD-1 increase, we evaluated apoptotic CD8 + T cells in splenocytes from chronically infected mice incubated for 5 h with anti-PDL-1 or control antibody (Fig.  S7) . Anti-PDL-1 treatment mediated reduction in apoptosis occurred primarily in the PD-1 int subset and only moderate decrease in apoptosis was noted in the PD-1 hi subset. To further address if anti-PDL-1 treatment was capable of rescuing preexisting PD-1 expressing CD8 + T cells in vivo, we adoptively transferred sorted PD-1 + CD8 + T cells from chronically infected CD45.1 mice (week 5-6) to similarly infected CD45.2 mice and then treated recipients with anti-PDL-1 antibody. Anti-PDL-1 treatment increased the absolute number of donor cells in both spleen and brain (Fig. S8) . However, although the recipient CD8 + T-cell population (comprising of both PD-1 + and PD-1 − ) expanded sixfold at the effector site (vis-à-vis isotype-treated), the donor population underwent over 20-fold expansion. This finding suggests that anti-PDL-1 treatment preferentially rescues preexisting PD-1-expressing cells.
Blockade of the PD-1-PDL-1 Pathway Controls Toxoplasma Recrudescence.
Finally, we wanted to address if this augmented CD8
+ T-cell response was able to control recrudescence by examining the gene expression of Toxoplasma parasites in brains of anti-PDL-1 or control antibody treated mice. Anti-PDL-1 treated mice revealed more of a bradyzoite-specific than tachyzoite-specific gene expression (Fig. 4A) . Moreover, anti-PDL-1 treated mice exhibited a much lower frequency of Toxoplasma-infected leukocytes in brain and blood than control group (Fig. 4B) . As previously stated, because encysted parasites can persist for life in immunocompetent host brains without causing pathology, we examined parasite genomic DNA in blood (6) . Detection of parasite DNA in blood by PCR has been used to diagnose cerebral toxoplasmosis in patents with AIDS (36) . As shown in Fig. 4C , parasite genomic DNA was only detectable in control antibody-treated and not in drug or anti-PDL-1 treated blood. Next, we monitored long-term survival of anti-PDL-1 treated mice. Surprisingly, although 100% of control mice died by day 91 postinfection, 90% of anti-PDL-1 treated mice survived until the termination (day 125 postinfection) of the experiment (Fig. 4D) . Furthermore, to demonstrate that increased survival of anti-PDL-1 treated mice was CD8-dependent, the surviving mice were treated with anti-CD8 antibody. As shown in Fig. 4E , CD8 depletion abrogated the survival of anti-PDL-1 treated animals. Taken together, the above data suggest that anti-PDL-1 treatment augments suboptimal CD8 + T-cell response in chronically infected mice, which prevents reactivation of infection leading to host survival.
Anti-PDL-1 Treatment Up-Regulates Eomes in CD8 + T Cells from
Chronically Infected Mice. T-box factors, T-bet and Eomesodermin, play a critical role in development, survival, and function of CD8 + T cells (37, 38) . Studies from our laboratory suggest that anti-PDL-1 treatment dramatically augments expression of Eomes but not T-bet (unaffected vis-à-vis acutely infected mice) in cycling CD8 + T cells (Fig. S9) . Incidentally, the critical role of Eomes in mediating CD8 + T-cell responsiveness to IL-15 (38), a cytokine crucial for survival of memory as well as effector CD8 + T cells, and Granzyme B (39-41) expression in T cells has been recently elucidated. Significantly, our data show that CD8 + T-cell dysfunction affects Granzyme B expression more than IFN-γ production. Significance of Eomes expression in our current model will have to await further investigation.
Discussion
CD8
+ T-cell exhaustion has been reported in several chronic viral infections, like LCMV, HBV, HCV, HIV, and Simian Immunodeficiency Virus, which are characterized by high levels of persisting viremia (42) . This exhaustion is manifested by the gradual loss of CD8 + T-cell effector functions (cytokine production, cytotoxicity, proliferation, and recall responses) and, in extreme situations, CD8 + T cells can be physically deleted (43) . In contrast, in infection models like murine cytomegalovirus, characterized by low levels of persistent viremia, antigen-specific T cells remain functional and respond vigorously to viral challenge (42, 44) . In models of reactivation like HSV that induce latent infection punctuated by periods of reactivation, functional long-lived CD8 + T-cell response is generated (45) . Based on these findings, it has been suggested that CD8 + T-cell exhaustion occurs only in the presence of uncontrolled persistent viremia (42, (46) (47) (48) . Our current report documents that CD8 + T-cell dysfunction is not restricted to viral infections alone but can be extended to intracellular protozoan parasite, like T. gondii. Although CD8 + T-cell dysfunction observed in the present study is similar in certain facets to certain viral pathogens, in its dependence on PD-1-PDL-1 interaction, it discounts the conventional paradigm that CD8 + T-cell exhaustion occurs only in infectious disease models with uncontrolled persistent pathogen load. Moreover, notwithstanding the fact that the role of the PD-1-PDL-1 pathway has been addressed in chronic viral models of CD8 + T-cell exhaustion, its significance in bacterial or parasitic models of CD8 + T-cell dysfunction has not been extensively investigated.
Our studies demonstrate that despite a potent development of CD8 + T-cell immunity during the early stages of chronic infection, endogenous CD8 + T-cell response is unable to control parasite reactivation at the later time points. This finding is in agreement with a previous study by Gazzinelli et al. (49) , which demonstrated that parasite reactivation in B6 mice during late-chronic phases is associated with increased expression of tachyzoite-specific genes in brain. Additionally, there is an increase in parasite levels in the periphery. A recent study has demonstrated the CD11b + leukocytes can act as shuttles for parasite migration during the acute infection phase (22) . Hence, it would be interesting to investigate in future studies whether during parasite reactivation, CD11b + leukocytes, which are preferentially parasitized during the latechronic phase, potentially serve a similar function and its role in mediating disease pathogenesis. Cumulatively, our results show that long-term exposure to a persistent pathogen despite initial control of parasitemia can lead to CD8 + T-cell dysfunction and parasite reactivation. This CD8 exhaustion with concomitant PD-1 up-regulation is characterized by reduced effector-cell numbers, decreased polyfunctionality, increased apoptosis, and poor recall response and expansion. Preliminary studies using drug treatment suggest that control of infection during the early but not later phases is critical for minimizing PD-1 up-regulation and CD8 dysfunction. This finding suggests that high antigen burden or inflammation (including anti-inflammatory cytokines) or both that occurs during acute phase of infection may be primarily responsible for defective development of a long-lived robust CD8 response during the chronic phase (42, 50) . Based on a recent study by Chang et al. (32) demonstrating that T-cell fate imprinting can occur as early as the first cell division, it is hardly surprising that T-cell microenvironment (cytokine, antigen burden, and so forth) during the early phase of Toxoplasma infection can have such a profound effect during the later phases. Our findings are further supported by a study in an LCMV model where antigen burden has been shown to be the key determinant for development of CD8 dysfunction (42) . However, any control of infection or antigen burden can potentially affect inflammation. Hence, in future studies it will be critical to discriminate the differential role of inflammatory milieu and antigen burden in mediating CD8 dysfunction.
Recent reports have identified role of IL-10 in mediating dysfunctional CD8 + T-cell response during LCMV infection (51). However, anti-IL10R treatment of mice carrying chronic Toxoplasma infection led to their increased mortality because of a strong inflammatory response (52) . This finding suggests that any strategy for preventing Toxoplasma reactivation must involve an appropriate balance between enhanced proinflammatory mediators without excessive suppression of anti-inflammatory factors. Interestingly, anti-PDL-1 treatment not only augmented the CD8 + T-cell response but also prevented mortality in chronically infected mice by controlling parasite reactivation.
How blockade of the PD-1-PDL-1 pathway modulates CD8 + T-cell response at the molecular level is poorly understood in infectious disease models. Recent studies have shown that differential TCR signal strength can affect not only memory CD8 programming but also development of a potent polyfunctional CD8 response (53, 54) . Considering that PD-1 ligation has been shown to inhibit TCR signaling via down-regulation of ZAP-70 and PKCθ in vitro, it is possible that anti-PDL-1 treatment restores robust CD8 response during chronic Toxoplasma infection via increased TCR sensitivity (55) . Although the mechanistic basis of CD8 dysfunction and PD-1 up-regulation need to be investigated more thoroughly in future studies, the data presented in this article provide significant insights into the role of PD-1-PDL-1 pathway in mediating CD8 + T-cell dysfunction and concomitant parasite reactivation. These results are especially significant in view of a minimal role played by CTLA-4, a related inhibitory molecule in regulating T-cell response during TE (56) . Our findings have important implications in the use of PD-1-PDL-1 blockade in combination with drug regimen for controlling TE in immunocompromised patients, as well as use of similar therapy in other dysfunction-induced reactivationtype diseases.
Materials and Methods
Mice, Parasites, and in Vivo Antibody Treatment. Female C57BL/6, CD45.1, and CD90.1 mice were purchased from the National Cancer Institute or the Jackson Laboratory. Animal studies were carried out in agreement with Institutional Animal Care and Use Committee approved guidelines. Unless otherwise mentioned, T. gondii cysts of ME49 strain were used for i.g. infection throughout. Some mice were injected in vivo with the following antibodies i.p.: anti-PDL-1 (MIH5) or anti-CD8 (2.43) or isotype-matched control antibodies.
Lymphocyte Isolation, Cell Surface Staining, and Intracellular Staining. Single cell suspension was prepared from spleen, liver, blood, and brain using standard protocol. For cytokine detection, 5 × 10 5 naïve congenic splenocytes was mixed with equal number of brain or splenic cells from infected mice, and restimulation was similarly carried out in the presence of TLA. To minimize the development of an allogeneic response, the antibody was administered with 2-wk interruptions until termination of the experiment. (E) Surviving anti-PDL-1 treated mice from the previous experiment were administered anti-PDL-1 along with anti CD8 (n = 4) or anti-PDL-1 and control antibody (n = 4) every third day unitl the conclusion of the experiment. Survival was monitored on a daily basis. Data represent two experiments.
